The overall goal of the Clinical Core is to provide the personnel, facilities, and organizational structure necessary to generate the research database and procure patients specimens for the basic and clinical studies proposed. It will be comprised of an already highly collaborative group of investigators that includes two pulmonologists, two research coordinators and consultants from thoracic radiology and lung pathology. In order to fulfill its overall goal, the Clinical Core will: C.1. Manage the identification, informed consent process, enrollment, and data collection of patients with suspected IPF undergoing surgical lung biopsy, of patients with IPF undergoing lung transplantation, and of control subjects undergoing thoracic sympathectomy via VATS or lung resection for bronchogenic carcinoma. Specific activities related to this function will include: a. Identify eligible patients. b. Obtain informed consent from patients. c. Enter patient's clinical, physiologic, radiologic and pathologic data into a comprehensive database. d. Coordinate procurement and processing of pleural mesothelial cells (PMCs) and lung fibroblasts (Fbs) to be delivered to the other cores and laboratories for the proposed studies. e. Coordinate interpretation of biopsy specimens by a multidisciplinary discussion to include clinicians, radiologist, and pathologist. C.2. Generate Research Forms and enter demographic and clinical data into the research module of P-TREC (UAB Pulmonary Translational Research and Clinical database). a. Maintain and update P-TREC and sample registry. b. Track patient sample delivery to individual laboratory. c. Provide patient demographic data to Project Leaders and Program Director.
The overall goal of the Clinical Core is to provide centralized and standardized procedures for the recruitment of subjects, procurement of specimens, diagnosis of ILD, and to populate a database with demographic and clinical information to support the projects of this application. The results from these studies may lead to the development of novel therapeutics for the treatment of Idiopathic Pulmonary Fibrosis, a devastating disease with no effective pharmacological therapy.
|Pennathur, Subramaniam; Vivekanandan-Giri, Anuradha; Locy, Morgan L et al. (2016) Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease. Am J Respir Crit Care Med 193:861-8|
|Liu, Rui-Ming; Eldridge, Stephanie; Watanabe, Nobuo et al. (2016) Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma. Am J Physiol Lung Cell Mol Physiol 310:L328-36|
|Larson-Casey, Jennifer L; Deshane, Jessy S; Ryan, Alan J et al. (2016) Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis. Immunity 44:582-96|
|Kurundkar, Ashish; Thannickal, Victor J (2016) Redox mechanisms in age-related lung fibrosis. Redox Biol 9:67-76|
|Kulkarni, Tejaswini; Willoughby, John; Acosta Lara, Maria Del Pilar et al. (2016) A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respir Med 115:33-8|
|Rangarajan, Sunad; Kurundkar, Ashish; Kurundkar, Deepali et al. (2016) Novel Mechanisms for the Antifibrotic Action of Nintedanib. Am J Respir Cell Mol Biol 54:51-9|
|Rangarajan, Sunad; Locy, Morgan L; Luckhardt, Tracy R et al. (2016) Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now? Drugs 76:291-300|
|Kulkarni, Tejaswini; de Andrade, Joao; Zhou, Yong et al. (2016) Alveolar epithelial disintegrity in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 311:L185-91|
|Cui, Huachun; Banerjee, Sami; Xie, Na et al. (2016) MicroRNA-27a-3p Is a Negative Regulator of Lung Fibrosis by Targeting Myofibroblast Differentiation. Am J Respir Cell Mol Biol 54:843-52|
|Swamy, Shobha M; Rajasekaran, Namakkal S; Thannickal, Victor J (2016) Nuclear Factor-Erythroid-2-Related Factor 2 in Aging and Lung Fibrosis. Am J Pathol 186:1712-23|
Showing the most recent 10 out of 51 publications